Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)

China · Delayed Price · Currency is CNY

12.92

+0.31 (2.46%)

Aug 20, 2026, 3:00 PM CST

-1.45% (1Y)

Market Cap	5.23B -1.7%
Revenue (ttm)	1.68B -21.4%
Net Income	48.72M -81.3%
EPS	0.12 -81.4%
Shares Out	404.74M
PE Ratio	110.47
Forward PE	n/a
Dividend	0.06 (0.47%)
Ex-Dividend Date	Jun 30, 2026

Volume	10,481,200
Open	12.86
Previous Close	12.61
Day's Range	12.66 - 13.12
52-Week Range	9.51 - 17.46
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHA:603439

Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonifying, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointments. In addition, the company trades medicinal herbs. Guizhou Sanli Pharm... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1995

Employees 1,887

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603439

Full Company Profile

Financial Performance

In 2025, SHA:603439's revenue was 1.70 billion, a decrease of -20.59% compared to the previous year's 2.14 billion. Earnings were 46.25 million, a decrease of -83.12%.

Financial Statements